At Nitrome Biosciences, Vu is isolating and characterizing enzymes. He is an innovative scientist with significant accomplishments in applying multidisciplinary approaches to develop therapeutics by establishing models for pain, aging, neuroinflammation and neurodegenerative diseases. He previously was project leader for internal research and development programs at NeuCyte.
Vu developed cellular assays to identify rejuvenating and aging factors in plasma at Alkahest and developed and implemented assays to screen for therapeutic molecules for multiple sclerosis and pain management at Teva. At iPierian, he was instrumental in the development of IPN007, an antibody for which BMS acquired iPierian and is currently owned by Biogen and in pivotal clinical trials for Progressive Supranuclear Palsy and Phase 2 trial for Alzheimer’s disease. Vu received his Ph. D. in Physiology and Pharmacology at Oregon University and BA in Biology at University of Portland.